The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company (NASDAQ:MDCO)

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MDCO
  • CUSIP: 58468810
  • Web:
  • Market Cap: $2.45884 billion
  • Outstanding Shares: 72,639,000
Average Prices:
  • 50 Day Moving Avg: $36.16
  • 200 Day Moving Avg: $42.45
  • 52 Week Range: $30.80 - $55.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.78
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $105.76 million
  • Price / Sales: 24.49
  • Book Value: $1.99 per share
  • Price / Book: 17.92
  • EBIDTA: ($300,670,000.00)
  • Net Margins: -670.46%
  • Return on Equity: -137.20%
  • Return on Assets: -45.68%
  • Debt-to-Equity Ratio: 2.14%
  • Current Ratio: 0.85%
  • Quick Ratio: 0.71%
  • Average Volume: 1.20 million shs.
  • Beta: 0.86
  • Short Ratio: 19.83

Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines Company's earnings last quarter?

The Medicines Company (NASDAQ:MDCO) posted its quarterly earnings data on Wednesday, August, 9th. The company reported ($5.52) EPS for the quarter, missing the consensus estimate of ($1.29) by $4.23. The firm earned $18.74 million during the quarter, compared to analysts' expectations of $29.64 million. The Medicines Company had a negative net margin of 670.46% and a negative return on equity of 137.20%. The Medicines Company's revenue for the quarter was down 65.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.62) EPS. View The Medicines Company's Earnings History.

When will The Medicines Company make its next earnings announcement?

The Medicines Company is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for The Medicines Company.

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

10 brokerages have issued 12 month target prices for The Medicines Company's shares. Their predictions range from $44.00 to $85.00. On average, they anticipate The Medicines Company's stock price to reach $55.44 in the next year. View Analyst Ratings for The Medicines Company.

What are analysts saying about The Medicines Company stock?

Here are some recent quotes from research analysts about The Medicines Company stock:

  • 1. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also optimistic about the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the industry in the last one year. However, the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Therefore, any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (8/8/2017)
  • 2. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)

Who are some of The Medicines Company's key competitors?

Who are The Medicines Company's key executives?

The Medicines Company's management team includes the folowing people:

  • Stuart A. Kingsley, President, Chief Operating Officer
  • Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director
  • William Bernard O'Connor, Chief Financial Officer
  • Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer
  • Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer
  • Stephen M. Rodin J.D., General Counsel, Secretary
  • Fredric N. Eshelman Pharm.D., Independent Non-Executive Chairman of the Board
  • Paris Panayiotopoulos, Director
  • William W. Crouse, Independent Director
  • Alexander J. Denner Ph.D., Independent Director

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.23%), Vanguard Group Inc. (8.57%), Iridian Asset Management LLC CT (5.17%), Aviva Holdings Ltd. (4.79%), State Street Corp (3.06%) and Westfield Capital Management Co. LP (2.86%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Aviva Holdings Ltd., Teachers Advisors LLC, First Eagle Investment Management LLC, Elk Creek Partners LLC, Pinnacle Associates Ltd., Parametric Portfolio Associates LLC and Virtu KCG Holdings LLC. Company insiders that have sold The Medicines Company stock in the last year include Clive Meanwell and William Bernard O'connor. View Insider Buying and Selling for The Medicines Company.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Iridian Asset Management LLC CT, Franklin Resources Inc., Macquarie Group Ltd., State Street Corp, Renaissance Technologies LLC, Creative Planning and Marshall Wace North America L.P.. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines Company's stock price today?

One share of The Medicines Company stock can currently be purchased for approximately $35.66.

MarketBeat Community Rating for The Medicines Company (NASDAQ MDCO)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  507
MarketBeat's community ratings are surveys of what our community members think about The Medicines Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $55.44 (55.48% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Chardan CapitalReiterated RatingBuy$85.00LowView Rating Details
9/14/2017Jefferies Group LLCReiterated RatingBuy$54.00LowView Rating Details
8/17/2017Oppenheimer Holdings, Inc.Set Price TargetHold$50.00LowView Rating Details
8/14/2017Citigroup Inc.Lower Price TargetNeutral$45.00 -> $44.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingBuy$61.00 -> $54.00HighView Rating Details
5/23/2017CIBCSet Price Target$50.00MediumView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/18/2016GuggenheimReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingBuyN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for The Medicines Company (NASDAQ:MDCO)
Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)
Earnings History by Quarter for The Medicines Company (NASDAQ MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017($1.37)N/AView Earnings Details
8/9/2017Q2 2017($1.29)($5.52)$29.64 million$18.74 millionViewListenView Earnings Details
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20173($1.79)($1.55)($1.65)
Q4 20173($1.33)($1.26)($1.30)
(Data provided by Zacks Investment Research)


Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
DateHeadline logoChardan Capital Reaffirms "Buy" Rating for The Medicines Company (MDCO) - September 20 at 8:20 PM logoZacks: Analysts Anticipate The Medicines Company (MDCO) to Announce -$1.58 EPS - September 17 at 10:30 PM logoThe Medicines Company (MDCO) Rating Reiterated by Jefferies Group LLC - September 14 at 7:16 PM logoETFs with exposure to The Medicines Co. : September 13, 2017 - September 14 at 7:36 AM logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 - September 12 at 12:59 AM logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : September 8, 2017 - September 9 at 6:08 AM logoTiGenix obtains commercial production license for expanded manufacturing facility - September 5 at 1:44 AM logoThe Medicines Company Expected to Earn Q3 2017 Earnings of ($1.79) Per Share (MDCO) - September 1 at 6:56 AM logo Brokerages Expect The Medicines Company (MDCO) Will Announce Quarterly Sales of $22.29 Million - September 1 at 5:22 AM logoFDA OKs The Medicines Company's Vabomere antibiotic; shares ahead 6% premarket - September 1 at 3:56 AM logoThe Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam) - September 1 at 3:56 AM logoMedicines Co. shares surge 2.5% on FDA approval of drug for complicated UTIs - September 1 at 3:56 AM logoThe Medicines Company's Infection Drug Vabomere Gets FDA Nod - September 1 at 3:56 AM logoOppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE - Yahoo News - August 31 at 7:09 AM logoThe Medicines Company (MDCO) Receives Average Recommendation of "Buy" from Analysts - August 30 at 2:32 PM logoMedicines Company Gets FDA Approval, Has 119% Upside According To This Analyst - August 30 at 2:20 PM logoThe Medicines Co. breached its 50 day moving average in a Bullish Manner : MDCO-US : August 29, 2017 - August 30 at 6:28 AM logoMedicines Company up 4.8% amid FDA approval for Vabomere - August 29 at 8:04 PM logoThe Medicines Company (MDCO) Given New $85.00 Price Target at Chardan Capital - August 29 at 8:40 AM logoMedicines Co. (MDCO), Alnylam (ALNY) Announces New, Positive Data from ORION-1 Phase II Study of Inclisiran - - August 28 at 8:21 PM logoAlnylam and The Medicines Company's inclisiran shows significant treatment effect in mid-stage study - Seeking Alpha - August 28 at 8:21 PM logoNew, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials - August 28 at 3:20 PM logoOppenheimer Holdings, Inc. Analysts Give The Medicines Company (MDCO) a $50.00 Price Target - August 19 at 10:54 PM logoCitigroup Inc. Lowers The Medicines Company (MDCO) Price Target to $44.00 - August 14 at 9:52 PM logoQ3 2017 EPS Estimates for The Medicines Company Reduced by Leerink Swann (MDCO) - August 14 at 2:50 AM logoOppenheimer Holdings Analysts Boost Earnings Estimates for The Medicines Company (MDCO) - August 14 at 2:50 AM logoThe Medicines Company Forecasted to Earn Q3 2017 Earnings of ($1.60) Per Share (MDCO) - August 14 at 2:50 AM logoTheStreet Downgrades The Medicines Company (NASDAQ:MDCO) to D - August 11 at 3:24 PM logoThe Medicines Company (NASDAQ:MDCO) Issues Quarterly Earnings Results - August 11 at 2:06 PM logoThe Medicines Company (MDCO) PT Lowered to $54 at Cowen; Reiterates Outperform - August 11 at 6:24 AM logoJefferies Group LLC Reaffirms Buy Rating for The Medicines Company (MDCO) - August 10 at 9:34 PM logoThe Medicines Company (MDCO) Earns "Buy" Rating from Cowen and Company - August 10 at 2:16 PM logoThe Medicines (MDCO) Q2 2017 Results - Earnings Call Transcript - August 10 at 5:01 AM logoInvestor Network: Medicines Company to Host Earnings Call - August 10 at 5:01 AM logoThe Medicines Company Reports Second Quarter 2017 Business and Financial Results - August 10 at 5:01 AM logoSee what the IHS Markit Score report has to say about Medicines Co. - August 10 at 5:01 AM logoEdited Transcript of MDCO earnings conference call or presentation 9-Aug-17 12:30pm GMT - August 10 at 5:01 AM logoMedicines Co. reports 2Q loss - August 10 at 5:01 AM logoMedicines Company (MDCO) option IV up into Q2 - - August 8 at 11:25 PM logoThe Medicines Company (NASDAQ:MDCO) Receives Average Rating of "Buy" from Analysts - August 5 at 2:38 PM logoThe Medicines (NASDAQ:MDCO) and Merus Labs International (MSLI) Head-To-Head Survey - August 5 at 12:46 PM logoThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : August 5, 2017 - August 5 at 2:38 AM logoThe Medicines Company (MDCO) to Release Earnings on Wednesday - August 3 at 11:16 AM logoThe Medicines Company Stock Attractively Priced Ahead Of FDA Decision - July 31 at 8:06 PM logoThe Medicines Company to Announce Second-Quarter 2017 Financial Results on August 9 - July 31 at 8:06 PM logoORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 - July 28 at 2:42 PM logoThe Medicines Company (MDCO) PT Raised to $45.00 - July 26 at 5:38 PM logoZacks: Analysts Anticipate The Medicines Company (NASDAQ:MDCO) Will Post Quarterly Sales of $30.51 Million - July 26 at 10:40 AM logoLate-stage study of The Medicines Co's antibiotic combo Vabomere stopped early; U.S. approval likely this quarter; shares ahead 5% premarket - July 26 at 4:48 AM logoThe Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE - July 26 at 4:48 AM



The Medicines Company (MDCO) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff